Previous 10 | Next 10 |
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma -COASTAL is intended to support FDA and global marketing approvals in patients with relapsed...
MEI Pharma (NASDAQ:MEIP) announces that chief financial officer Brian Drazba has informed the company that he is retiring. Drazba, an industry veteran who has overseen financial operations since joining in April 2017, will continue to serve in his current role and provide trans...
MEI Pharma Announces Planned Chief Financial Officer Transition Brian Drazba, Chief Financial Officer of MEI Pharma, to Retire at the End of 2021 PR Newswire SAN DIEGO , Aug. 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceu...
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO , July 1, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announce...
4 Penny Stocks To Watch This Week With Upcoming Events Penny stocks can be fickle. On the one hand, many will move with different market trends. On the other hand, they may be completely disconnected from broader sentiment. This month, we’ve seen both of these instances, with eve...
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program PR Newswire SAN DIEGO and TOKYO , June 9, 2021 /PRNewswire/ --...
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib - New Marginal Zone Arm of TIDAL Study Intended to Support Accelerated Approval Application with the U.S. Food and Drug Administration...
MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting -- Event Scheduled for Thursday, June 10, 2021 at 12:00 PM Eastern Time Featuring Deepa Jagadeesh, M.D. -- PR Newswire SAN DIEGO , June 4, 2021 /PRNewswire/ -- MEI ...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
MEI Pharm (MEIP) says that new data from two phase 1 trials of its phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor zandelisib showed strong response rates in lymphoma and malignancies.In one of the studies, all patients with relapsed/refractory indolent B-cell malignancies...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...